33184-56-4

Upstream product

• 7446-70-0 aluminium trichloride 
• 118-45-6 4-chlorophthalic anhydride 
• 71-43-2 benzene 
• 122-01-0 4-chloro-benzoyl chloride 
• 74-11-3 para-chlorobenzoic acid 
• 25563-14-8 4-chloro-N-methoxybenzamide 
• 100-52-7 benzaldehyde 
• 611-73-4 Benzoylformic acid 
• 7499-06-1 5-chloro-2-methylbenzoic acid 
• 33184-55-3 5-chloro-2-methyl-benzophenone 
• 57892-55-4 2-benzoyl-4-chlorobenzonitrile 

Downstream Products

• 120116-65-6 6-chloro-4-phenylphthalazine-1(2H)-one 
• 131-09-9 2-chloroanthracene-9,10-dione 
• 21143-54-4 2-Benzyl-4-chlorobenzyl alcohol 
• 21143-55-5 2-Benzyl-1-bromomethyl-4-chloro-benzene 
• 21143-56-6 (2-Benzyl-4-chloro-phenyl)-acetonitrile 
• 21143-57-7 (2-Benzyl-4-chloro-phenyl)-acetic acid 
• 21143-53-3 methyl 2-benzyl-4-chlorobenzoate 
• 81992-90-7 2-benzyl-4-chloro-benzoic acid 
• 142256-41-5 6-chloro-1-oxo-4-phenyl-1H-isochromene-3-carboxylic acid 
• 142256-52-8 3-amino-6-chloro-2-methyl-4-phenylisoquinolin-1(2H)-one 
• 1332696-99-7 3-(2-aminoethyl)-6-chloro-2-methyl-4-phenylisoquinolin-1(2H)-one hydrochloride 
• 1332697-19-4 tert-butyl [2-(6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl]carbamate 
• 1332697-20-7 3-(6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)propanoic acid 
• 1332697-21-8 diethyl 2-[(6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)methyl]propane-1,3-dioate 

Relevant academic research and scientific papers

Synthesis of biaryl imino/keto carboxylic acids via aryl amide directed C-H activation reaction

A novel Pd-catalysed C-H activation reaction for the synthesis of biaryl imino/keto carboxylic acids is developed. This reaction underwent aryl amide directed C-H activation ortho-acylation followed by ring closing and ring opening processes to give a range of biaryl imino/keto carboxylic acids. Our methodology features the utilization of a cheap and green oxidant (TBHP) as well as readily available aldehydes.

Palladium-catalyzed chemoselective decarboxylative ortho acylation of benzoic acids with α-oxocarboxylic acids

Palladium-catalyzed chemoselective decarboxylative cross coupling of benzoic acids with α-oxocarboxylic acids was realized via an arene sp 2 C-H functionalization process. This work represents the first example of transition-metal-catalyzed cro

2-Hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic Acid with Inbuilt β-NHydroxy-γ-keto-Acid pharmacophore as HCV NS5B polymerase inhibitors

The inbuilt 2-N-hydroxy-1-oxo-3-carboxylic acid of isoquinolone was designed as pyrophosphate mimic for hepatitis C NS5B polymerase. Various 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid derivatives 11a-p were synthesized and evaluated as HCV NS5B polymerase inhibitors. Compound 11c exhibited moderate inhibitory potency based on the inorganic pyrophosphate generation (IC50 = 9.5 μM) and based on NTP incorporation by NS5B enzyme (IC50 = 5.9 μM). Compound 11c demonstrated antiviral activity (EC50 = 15.7 μM) and good selectivity in HCV genotype 1b replicon Ava.5 cells. Compound 11c reduced the interaction of NTP to NS5B polymerase. Docking model showed that 11c situated in similar orientation to the bound uridine triphosphate in the active site of NS5B polymerase. As a result, 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid was disclosed as a novel inbuilt β-Nhydroxy-γ-keto-acid pharmacophore for HCV NS5B polymerase inhibitors.

Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554

The design, synthesis, and structure-activity relationships of a new class of potent and orally active non-peptide dipeptidyl peptidase IV (DPP-4) inhibitors, 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones, are described. We hypothesized that the 4-ph

Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1)

A novel series of 4-phenylisoquinolones were synthesized and evaluated as c-Jun N-terminal kinase (JNK) inhibitors. Initial modification at the 2- and 3-positions of the isoquinolone ring of hit compound 4, identified from high-throughput screening, led to the lead compound 6b. The optimization was carried out using a JNK1-binding model of 6b and several compounds exhibited potent JNK inhibition. Among them, 11g significantly inhibited cardiac hypertrophy in rat pressure-overload models without affecting blood pressure and the concept of JNK inhibitors as novel therapeutic agents for heart failure was confirmed.

JNK INHIBITOR

A JNK inhibitor containing a compound having an isoquinolinone skeleton or a salt thereof, such as a compound represented by the formula wherein ring A and ring B are each an optionally substituted benzene ring, X is -O-, -N=, -NR3- or -CHR3-, R2 is an acyl group, an optionally esterified or thioesterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group and the like, a broken line shows a single bond or a double bond, and R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like, and the like.

Selective Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. New 2,3-Dihydrothiazoloisoindol-5(9bH)-ones and Related Compounds with Anti-HIV-1 Activity

A series of substituted 2,3-dihydrothiazoloisoindol-5(9bH)-ones and related compounds 1-73 were synthesized and evaluated for their ability to inhibit reverse transcriptase (RT) of the human immune deficiency virus 1 (HIV-1) and replication of HIV-